Circulating Tumor DNA and Late Recurrence in High-Risk Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer.
Marla Lipsyc-SharfElza C de BruinKatheryn SantosRobert McEwenDaniel StetsonAshka PatelGregory J KirknerMelissa E HughesSara M TolaneyAnn H PartridgeIan E KropCharlene KnapeUte FegerGiovanni MarsicoKaren HowarthEric P WinerNancy U LinHeather A ParsonsPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
In this prospective study, in patients with high-risk HR+ BC in the late adjuvant setting, ctDNA was identified a median of 1 year before all cases of distant metastasis. Future studies will determine if ctDNA-guided intervention in patients with HR+ BC can alter clinical outcomes.